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Association between decreased 
serum tBIL concentration and 
immediate memory impairment in 
schizophrenia patients
Xiao Li Yin1, Qiu Fang Jia2,3, Guang Ya Zhang2, Jian ping Zhang4,5, tomoaki shirao6, 
Cai Xia Jiang2, Xu Yuan Yin2, Yan song Liu2, peng Chen2, Xiao Chu Gu2, Zheng Kang Qian2, 
Guang Zhong Yin2, Hai sen Xia7 & Li Hui1,2,3
Cognitive impairment is a core feature of schizophrenia (SCH). In addition to the toxic effect of Bilirubin 
(BIL), it has antioxidant properties that were associated with the psychopathology and cognitive 
impairment of psychiatric disorders. The aim of this study was to examine the correlation of serum total 
BIL (TBIL) concentration with cognitive impairment in SCH patients. We recruited 34 SCH patients and 
119 healthy controls (HCs) in this case-control design. Cognition was assessed using the Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS). Serum TBIL concentration was 
measured using the immunoturbidimetric method. Serum TBIL concentration was significantly 
decreased in sCH patients compared to HCs after adjusting for age, gender, and education. serum 
TBIL concentration in SCH patients was also positively correlated with the RBANS immediate memory 
score. Further stepwise multiple regression analysis confirmed the positive association between serum 
TBIL concentration and immediate memory score in SCH patients. Our findings supported that the 
decline in serum TBIL concentration was associated with the immediate memory impairment and 
psychopathology of SCH.
Schizophrenia (SCH) is a severe psychiatric disorder that affects around 0.7% of the population worldwide1. 
Although SCH primarily involves a series of psychiatric symptoms, cognitive impairment is regarded as a core 
feature of SCH that precedes the onset of psychotic symptoms, and persists throughout the illness course2–6. 
SCH-associated cognitive impairment emerges in almost all cognitive domains, and may influence treatment 
outcomes, rehabilitation, quality of life, and even employment7–14. Collectively, these findings support the notion 
that cognitive impairment should be considered a potential treatment target for SCH and an important focus 
of future studies. However, the underlying pathophysiology of cognitive impairment in SCH patients remains 
unclear and requires further investigation.
Bilirubin (BIL) is a powerful antioxidant that is believed to stem from heme15,16. It has been reported that 
BIL demonstrates a strong protective function in the body when the mechanism of defense against oxidative 
stress is challenged17. Interestingly, both increased and decreased total BIL (TBIL) concentration (or a diversity 
of BIL-related effects) associated with SCH patients has been reported in previous studies. For example, sev-
eral studies have shown that plasma TBIL concentration in SCH patients is significantly decreased compared to 
healthy controls (HCs)18–22. Similarly, plasma TBIL concentration in first-episode SCH patients is found to be 
significantly lower than that in HCs22. Further study has indicated that both male and female SCH patients have 
an approximately two-fold lower BIL concentration compared to HCs23. Moreover, the urinary concentration of 
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biopyrrins generated from BIL in SCH patients is significantly higher than that in HCs24,25. These studies support 
the hypothesis that the antioxidant system defects exist in SCH patients26,27. However, two recent studies have 
indicated that serum BIL concentration in SCH patients is significantly elevated compared to HCs28,29. Also, 
previous studies have shown that there is a significant association between moderate hyperbilirubinemia and 
SCH24,30–34. Therefore, further studies should be conducted to resolve the inconsistency among these findings.
Previous studies have shown that abnormal BIL concentration may influence cognitive function. For example, 
serum BIL concentration is reported to be positively correlated with the Mini-Mental State Examination scores 
and Montreal Cognitive Assessment (including attention, delayed recall and abstract) in patients with mild cog-
nitive impairment (MCI)35. Another study finds a positive correlation between serum BIL concentration and 
cognitive function originated from a great number of cognitive domains in patients with subcortical ischemic 
vascular disease (SIVD)36. Abnormal concentration of BIL in the brain can cause microglia and astrocyte activa-
tion, impaired myelination, and neuronal cell death37. Moreover, serum TBIL concentration in Korean adults is 
closely associated with the leukoaraiosis, which is relevant to cognitive impairment38–41. These findings indicate 
that serum TBIL concentration may influence cognitive function in SCH patients. However, to our knowledge, 
no study has investigated the relationship between serum TBIL concentration and cognitive impairment in SCH 
patients. Therefore, the objective of this study was to examine whether serum TBIL concentration is significantly 
associated with cognitive impairment in SCH patients in a Chinese population.
Results
Sociodemographic and clinical characteristics. Table 1 showed the sociodemographic and clinical 
characteristics of all subjects. SCH patients and HCs did not differ in age, gender, and education. There were 
significant differences in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total 
score and subscores of immediate memory, attention, language, and delayed memory between the two groups. 
These between-group differences remained significant after adjusting for age, gender and education. These sig-
nificant cognitive differences also passed the Bonferroni correction. Further Pearson’s correlation analysis found 
that serum TBIL concentration was not related to the Positive and Negative Syndrome Scale (PANSS) total score, 
PANSS negative symptom, PANSS positive symptom, and PANSS general psychopathology in SCH patients.
serum tBIL concentration between sCH patients and HCs. Figure 1 showed that serum TBIL 
concentration in SCH patients was significantly decreased compared to HCs. This between-group difference 
remained significant after adjusting for age, gender and education.
Associations of serum tBIL concentration with the RBANs scores. The Pearson’s correlation anal-
ysis found a linear correlation of serum TBIL concentration with the immediate memory score in SCH patients, 
but not in HCs, as shown in Fig. 2. There were no significant correlations between serum TBIL concentration 
and other cognitive scores in SCH patients and HCs, respectively. Moreover, there were no relationships between 
serum TBIL concentration and cognitive scores in HCs with higher TBIL concentration (>11.14 umol/L or 
>14.00 umol/L).
Stepwise multiple regression analysis further indicated that serum TBIL concentration in SCH patients was 
related to the immediate memory score. In contrast, serum TBIL concentration in SCH patients was not associ-
ated with other cognitive scores (i.e., subscales of visuospatial/constructional, attention, language, and delayed 
memory, and RBANS total score). Moreover, serum TBIL concentration was not associated with the cognitive 
scores in HCs.
Variables
SCH Patients 
(n = 34) HCs (n = 119) P Value
Sex (male/female) 21/13 71/48 0.83
Age (years) 47.74 ± 10.02 45.71 ± 9.93 0.30
Education (years) 10.88 ± 3.12 11.63 ± 3.94 0.31
Age of Onset (years) 25.03 ± 7.14
PANSS-Positive Symptom 12.06 ± 4.53
PANSS-Negative Symptom 18.03 ± 8.03
PANSS-General Psychopathology 26.68 ± 6.75
PANSS-Total Score 56.76 ± 15.85
RBANS-Immediate Memory 68.88 ± 18.72 93.03 ± 15.66 3.22 × 10−12
RBANS-Attention 87.03 ± 15.45 112.86 ± 15.99 3.67 × 10−14
RBANS-Language 85.71 ± 12.91 98.21 ± 12.60 1.12 × 10−6
RBANS-Visuospatial/Constructiona 89.71 ± 19.54 86.01 ± 13.27 0.90
RBANS-Delayed Memory 77.79 ± 16.49 94.35 ± 7.74 6.84 × 10−14
RBANS-Total Score 76.97 ± 14.55 91.41 ± 14.17 2.73 × 10−13
Table 1. The sociodemographic and clinical characteristics in SCH patients and HCs. Note: Mean ± SD, 
SCH = schizophrenia; Healthy controls = HCs; PANSS = Positive and negative syndrome scale.
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Figure 1. Comparison of serum TBIL concentration between SCH patients and HCs. Serum TBIL 
concentration was significantly lower in SCH patients than that in HCs (9.74 ± 3.38 vs. 11.14 ± 3.49 umol/L, 
F = 4.35, p = 0.04). Abbreviations: SCH, schizophrenia; HCs, healthy controls.
Figure 2. Correlation of serum TBIL concentration with the immediate memory score in SCH patients (a) 
and HCs (b). A significant correlation was found in SCH patients (r = 0.46, n = 34, p = 0.007), but not in HCs 
(r = -0.07, n = 119, p = 0.48).
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Discussion
Our study showed that SCH patients had more severe cognitive impairment than HCs in most cognitive domains, 
except for the visuospatial/constructional domain, which is in line with our previous findings9,10,42. This finding 
is supported by several longitudinal and cross-sectional studies in first-episode SCH patients43–45. Interestingly, 
cognitive impairment has been found to be closely associated with the abnormality of leukoaraiosis that was 
influenced by the decreased BIL concentration in a sample of Korean adults38–41. Specifically, the change in BIL 
concentration may lead to microglia and astrocyte activation, myelination damage, and apoptosis of neuron cells 
in the brain37. These findings suggest that BIL might play a critical role in cognitive impairment. In the present 
study, serum TBIL concentration was positively correlated with the immediate memory score in SCH patients 
in a Chinese population. It is hypothesized that the immediate memory impairment may be mediated through 
antioxidant system defects resulting from decreased TBIL concentration26,27,46,47. A recent study has found a posi-
tive correlation of serum TBIL concentration with the cognitive score in MCI35. Serum concentration of BIL also 
was significantly associated with the recent memory score in SIVD patients36. Thus, the underlying mechanism 
responsible for the association of serum TBIL concentration with the immediate memory score could reflect the 
abnormality of antioxidant system that could further lead to neuronal and microglia impairment of SCH brain. 
Also, future studies should investigate the associations between other antioxidants and immediate memory score 
in first-episode SCH patients to confirm our findings.
Moreover, our findings indicated that serum TBIL concentration was significantly lower in SCH patients 
than that in HCs, which is consistent with previous studies18–22. Another study found that serum BIL concen-
tration in HCs was approximately two-fold that in SCH patients23. Further studies have found that first-episode 
SCH patients had lower plasma TBIL concentration than HCs22,23. Compared to HCs, serum TBIL concentration 
also was significantly decreased in patients with major depressive disorder48. These findings further support the 
hypothesis that the defects of antioxidant defense system might be involved in the etiology of SCH26,27.
Several limitations should be noted in this study. First of all, our study had a relatively small sample size. These 
findings should be considered as preliminary. Second, it was a cross-sectional study design. Prospective studies 
with longitudinal follow-ups should be performed to confirm the association between serum TBIL concentra-
tion and immediate memory score in SCH patients. Thus, it is not clear whether there is a causal association 
of decreased serum TBIL concentration with the immediate memory deficits in SCH patients in this study. 
Furthermore, we did not differentiate direct and indirect BIL from TBIL because direct BIL was not measured. 
Additionally, although SCH patients were antipsychotic free for at least two weeks prior to this study, the effect 
of antipsychotics on serum BIL concentration could not be ruled out. Previous studies have indicated that antip-
sychotics and metabolic syndrome influence BIL concentration in SCH patients49,50. Thus, future studies should 
be performed in first-episode and drug-free SCH patients without metabolic syndrome. Finally, we did not collect 
other relevant data, including body mass index, alcohol intake, and smoking. Whether they might affect serum TBIL 
concentration and cognitive function in SCH patients, which should be further investigated in the future.
Collectively, we found that serum TBIL concentration was lower in SCH patients than that in HCs in a Chinese 
population. Serum TBIL concentration was positively associated with the immediate memory score in SCH 
patients. Our data further demonstrated that decreased TBIL concentration might reflect oxidant defense defects 
underlying the psychopathology of SCH. Also, the decline in serum TBIL concentration might play an important 
role in the immediate memory impairment in SCH patients. However, these findings should be regarded as pre-
liminary due to little sample size, missing related data of antipsychotics use and metabolic syndrome, and absence 
of a longitude design. Thus, future studies should confirm our present findings in first-episode and drug-free SCH 
patients in a larger prospective sample.
Methods
subjects. The sample size was calculated by an online website (http://powerandsamplesize.com/) according 
to the findings of previous studies51,52. The minimum sample size of this study was calculated for 32 SCH patients 
and 46 HCs. However, 34 SCH patients and 119 HCs (about 1:4 ratio) recruited in this study were further deter-
mined according to the previous study reporting 1: 4 case/control ratio for matched case-control studies to find 
valid associations with regards to the power53.
We recruited 34 SCH patients (male = 21, female = 13) at the inpatient unit of the Affiliated Guangji Hospital 
of Soochow University. The inclusion criteria included the following: (1) age between 18 and 60 years, Han 
Chinese; (2) diagnosis of schizophrenia as confirmed by two psychiatrists using the Structured Clinical Interview 
for DSM-IV (SCID); (3) no previous exposure to antipsychotics at least 2 weeks prior to the beginning of this 
study; 4) able to provide the signed informed consent and participate in the psychopathology assessment.
For comparison, 119 HCs (male = 71, female = 48) were recruited at the same time from Suzhou local com-
munity. They were all Han Chinese. Two psychiatrists assessed their present psychiatric status, and collected per-
sonal or family history of psychiatric disorders using unstructured interviews. They did not have any psychiatric 
disorders as well as family history of psychiatric disorders.
A complete medical history and physical examination were obtained from all subjects. Any subjects with other 
medical illness i.e. substance abuse/dependence, liver disorder, cancer, diabetes, and pregnancy were excluded. 
The Institutional Review Board of the Affiliated Guangji Hospital of Soochow University approved the informed 
consent and protocol of this study, and all experiments would be carried out in accordance with the approved 
guidelines and regulations. All subjects must sign informed consent before they participated in this study.
Clinical measure. Each subject filled out a detailed questionnaire that recorded the general information, 
sociodemographic characteristics, and medical conditions. Other information was obtained from the available 
electronic medical records.
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A clinical researcher used the RBANS to assess cognitive function in all subject54. The RBANS includes 12 sub-
tests that are used to calculate a total score and 5 age-adjusted index scores. The test indices consist of attention, 
immediate memory, visuospatial/constructional, delayed memory, and language. Our research group has previ-
ously translated the English version of the RBANS into Chinese, and established its clinical validity and test-retest 
reliability in HCs and SCH patients55. The RBANS index scores were the standardized scores in this study.
Two psychiatrists used the PANSS to assess the severity of SCH psychopathology56. They had simultaneously 
attended a training session in the PANSS use before the beginning of this study. After training, a correlation coef-
ficient greater more 0.8 was maintained for the PANSS total score by repeated assessments.
tBIL measurement. Serum samples were collected from the forearm vein between 7 and 9 AM following 
an overnight fast. The serum of samples was separated, aliquoted, and stored at −80  °C in a refrigerator before 
serum TBIL concentration was measured. We used a HITACHI automatic biochemistry analyzer (Mode: 7180, 
Japan) to measure serum TBIL concentration through the method of chemical oxidation using a commercially 
available kit (MedicalSystem Biotechnology, China). The sensitivity of this kit was 3.42 umol/L, and its intra- and 
inter-assay variation coefficients were 4% and 5%, respectively. For each sample, serum TBIL concentration was 
assessed in triplicate by our technician.
Statistical analysis. Since the sociodemographic and clinical characteristics including serum TBIL concen-
tration were normally distributed in SCH patients and HCs (1-Sample Kolmogorov-Smirnov test), the compar-
isons between the two groups with regard to the sociodemographic and clinical characteristics were performed 
using analysis of variance (ANOVA) and Chi-squared test. The potential confounding variables were added as the 
covariates while the significant differences in the RBANS scores and serum TBIL concentration were observed 
between the two groups. Bonferroni correction were applied to each test to adjust for potential Type I error infla-
tion due to multiple testing. Pearson’s correlation analyzed the correlations of serum TBIL concentration with the 
PANSS scores in SCH patients, and the associations of serum TBIL concentration with the RBNAS scores in SCH 
patients and HCs, respectively. Further stepwise multiple regression analysis was used to confirm the potential 
variables that might affect the RBANS scores in SCH patients and HCs. All statistical analyses were performed 
using the SPSS 17.0 for windows (SPSS Inc., Chicago, USA). The continuous variables were shown as mean and 
standard deviation (mean ± SD), and the statistical significance of all p values was set at 0.05 (2-sided).
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